Entropy Neurodynamics Limited ENP
ASX · Australia · Health Technology
AUD 0.0390+0.00 (+1.30%)
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Entropy Neurodynamics Ltd (ASX:ENP, OTC:TYPTF) has secured a pre-clinical trial agreement with the University of California, San Francisco (UCSF) for a proposed US Phase 2 study comparing its precision-controlled psychedelic therapy TRP-8803 directly with widely prescribed antidepressant...
Entropy Neurodynamics Limited ('Entropy Neurodynamics' or the 'Company') (ASX: ENP), a clinical-stage biotechnology company developing precision-controlled psychedelic therapies, advises that it has received Human Research Ethics Committee approval to commence a Phase 1b/2a multi-indication basket study evaluating TRP-8803 (IV-infused psilocin) across eight significant and widespread disorders. The Company has also entered into a Clinical Trial Research Agreement ('CTRA') with Swinburne Universi
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.